<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01263834</url>
  </required_header>
  <id_info>
    <org_study_id>EC 53-296-02-1-2</org_study_id>
    <nct_id>NCT01263834</nct_id>
  </id_info>
  <brief_title>Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome</brief_title>
  <acronym>Bevacizumab</acronym>
  <official_title>The Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prince of Songkla University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prince of Songkla University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the adjunctive effect of intratenon Bevacizumab on
      the result of trabeculectomy in primary term of intraocular pressure (IOP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective interventional clinical trial

      Single center, outcome assessor-masked, active control, randomized controlled trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleb characteristic grading</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic Blood pressure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Mitomycin c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin C</intervention_name>
    <description>Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application</description>
    <arm_group_label>Mitomycin c</arm_group_label>
    <other_name>MMC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary open angle glaucoma with primary mmc-trabeculectomy indication

        Exclusion Criteria:

          -  combined phacoemulsification with trabeculectomy

          -  no more than 6 month of cataract surgery before trabeculectomy

          -  revised trabeculectomy

          -  active uveitic glaucoma

          -  neovascular glaucoma

          -  par planar vitrectomy

          -  conjunctival surgery

          -  allergy to bevacizumab or mitomycin C

          -  ischemic heart disease

          -  cerebrovascular disease

          -  renal failure

          -  liver failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weerawat Kiddee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Songkla University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University</name>
      <address>
        <city>Hat-yai</city>
        <state>Songkhla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2010</study_first_submitted>
  <study_first_submitted_qc>December 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2010</study_first_posted>
  <last_update_submitted>January 30, 2014</last_update_submitted>
  <last_update_submitted_qc>January 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Prince of Songkla University</investigator_affiliation>
    <investigator_full_name>Weerawat Kiddee</investigator_full_name>
    <investigator_title>Dr.Weerawat Kiddee</investigator_title>
  </responsible_party>
  <keyword>Trabeculectomy</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>intraocular pressure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

